Diabetesa recent study conducted in Italy and published in The Lancet Regional Health Europe revealed that the anti-diabetic drug dapaglifozin, already in use, has a protective effect on the kidneys in patients with type 2 diabetes. This drug is able to reduce the kidney damage, maintaining the filtering function of the organs and delaying or preventing loss of kidney function that could lead to the need for dialysis or transplant.
Heart, from pollution to stress: the new risk factors. The cardiologist: «They interact in an unpredictable way»
The research, conducted in more than 50 Italian diabetes centers and involving 12,000 patients, highlighted that dapaglifozin is more effective in slowing down the decline in renal filtering capacity (measured by eGFR) and in reducing the increase in albuminuria ( indicator of kidney damage) compared to other antidiabetic drugs.
Additionally, dapaglifozin has been shown to significantly reduce the risk of developing new chronic kidney disease by 24% and the risk of loss of kidney function by 31% compared to other classes of diabetes medications.
Diabetic retinopathy, only 11% of people at risk have an annual eye exam
The president of the Italian Society of Diabetology, Angelo Avogaro, underlined the importance of these results, highlighting the potential impact of dapaglifozin in the prevention and treatment of chronic kidney disease in patients with type 2 diabetes, even in those at low risk renal, thus confirming the effectiveness of this drug in ensuring unprecedented renal protection.
© ALL RIGHTS RESERVED